CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Dronabinol 30mg/day +3 moredrug
Likely dose
Dronabinol 30mg/dayfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00893074
NCT00893074Phase 2Completed
CompareCT.gov

The Effect of Prescription Medications in Marijuana Users

Johns Hopkins University·interventional·Posted May 5, 2009·Updated Aug 3, 2017

In Brief

A Phase 2 clinical trial evaluating Dronabinol 30mg/day, Dronabinol 60mg/day, and 2 other interventions for Marijuana Abuse. Completed, enrolled 24 participants across 1 site.

Detailed Summary

A subset of heavy marijuana users have trouble quitting marijuana use and the number of those seeking treatment for problems related to marijuana is increasing. The purpose of this research study is to investigate whether dronabinol can reduce withdrawal effects associated with stopping marijuana use, if dronabinol can reduce the rewarding effects of smoked marijuana, and whether there are any cognitive performance deficits associated with dronabinol doses that produce such effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMarijuana Abuse
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 5, 2009
Enrollment StartApr 1, 2009
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 17.2 years ago

Interventions

Dronabinol 30mg/daydrug

10mg dronabinol administered 3x/day for 5 days

Dronabinol 60mg/daydrug

20mg dronabinol administered 3x/day for 5 days

Dronabinol 120mg/daydrug

40mg dronabinol administered 3x/day for 5 days

Placebodrug

placebo dronabinol administered 3x/day for 5 days